Disc Medicine annual shareholders’ equity
2020
2021
2022
2023
2024
2025
Disc Medicine Shareholders’ Equity Growth & History (IRON)
Disc Medicine's shareholders’ equity was $739.8M for fiscal 2025.
View full Disc Medicine company overviewDisc Medicine annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $739.8M | $296.2M | +66.78% |
| 2024 | 2024-12-31 | $443.6M | $98.5M | +28.53% |
| 2023 | 2023-12-31 | $345.1M | $168.5M | +95.43% |
| 2022 | 2022-12-31 | $176.6M | $240.8M | — |
| 2021 | 2021-12-31 | −$64.2M | −$35.4M | — |
| 2020 | 2020-12-31 | −$28.8M | — | — |
Disc Medicine quarterly shareholders’ equity
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $644.2M | $30.0M | +4.88% |
| Q1 2026 | 2026-03-31 | $688.4M | $28.1M | +4.25% |
| Q4 2025 | 2025-12-31 | $739.8M | $296.2M | +66.78% |
| Q3 2025 | 2025-09-30 | $573.4M | $105.4M | +22.53% |
| Q2 2025 | 2025-06-30 | $614.2M | $125.3M | +25.64% |
| Q1 2025 | 2025-03-31 | $660.4M | $322.3M | +95.33% |
| Q4 2024 | 2024-12-31 | $443.6M | $98.5M | +28.53% |
| Q3 2024 | 2024-09-30 | $468.0M | $109.0M | +30.36% |
| Q2 2024 | 2024-06-30 | $488.8M | $117.6M | +31.68% |
| Q1 2024 | 2024-03-31 | $338.1M | $105.2M | +45.19% |
| Q4 2023 | 2023-12-31 | $345.1M | $168.5M | +95.43% |
| Q3 2023 | 2023-09-30 | $359.0M | $457.5M | — |
| Q2 2023 | 2023-06-30 | $371.2M | $454.0M | — |
| Q1 2023 | 2023-03-31 | $232.9M | $306.5M | — |
| Q4 2022 | 2022-12-31 | $176.6M | $240.8M | — |
| Q3 2022 | 2022-09-30 | −$98.5M | −$239.4M | — |
| Q2 2022 | 2022-06-30 | −$82.8M | −$240.5M | — |
| Q1 2022 | 2022-03-31 | −$73.7M | −$244.8M | — |
| Q4 2021 | 2021-12-31 | −$64.2M | −$35.4M | — |
| Q3 2021 | 2021-09-30 | $140.9M | $149.1M | — |
| Q2 2021 | 2021-06-30 | $157.7M | — | — |
| Q1 2021 | 2021-03-31 | $171.2M | — | — |
| Q4 2020 | 2020-12-31 | −$28.8M | — | — |
| Q3 2020 | 2020-09-30 | −$8.3M | — | — |
Disc Medicine shareholders’ equity trends
Over the last five fiscal years, Disc Medicine's shareholders’ equity increased from −$28.8M to $739.8M, a change of $768.6M. The latest reported quarter, Q2 2026, shows $644.2M.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Disc Medicine source filings ↗Community posts
Disc Medicine prices an enlarged $450 million equity offering
Disc Medicine ($IRON) priced an upsized public offering of six million common shares at $75 each, generating expected gross proceeds of $450 million before underwriting discounts and expenses. Underwriters have a 30-day option to buy anothe ...
